Comparative Pharmacology
Head-to-head clinical analysis: JUNEL 1 5 30 versus JUNEL 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNEL 1 5 30 versus JUNEL 1 20.
JUNEL 1.5/30 vs JUNEL 1/20
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via estrogen and progestin negative feedback, inhibiting ovulation. Changes cervical mucus viscosity and endometrial lining to impede sperm penetration and implantation.
Combination estrogen-progestin contraceptive. Ethinyl estradiol is a synthetic estrogen that suppresses gonadotropin release by inhibiting hypothalamic GnRH secretion. Norethindrone acetate is a progestin that suppresses LH surge and thickens cervical mucus to inhibit sperm penetration and alters endometrial development.
Prevention of pregnancyTreatment of acne vulgaris (for women ≥15 years who have reached menarche and desire an oral contraceptive)
Prevention of pregnancy in women who elect to use oral contraceptivesTreatment of moderate acne vulgaris for women at least 15 years old who have achieved menarche and are willing to use an oral contraceptiveTreatment of menstrual disorders (off-label)Emergency contraception (off-label)
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily.
One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days, then repeat.
None Documented
None Documented
EE: terminal half-life ~17 ± 8 hours; NET: terminal half-life ~8 ± 1 hours. Steady-state achieved within ~2-3 cycles.
Ethinyl estradiol: 12-24 hours (terminal half-life). Norethindrone: 5-14 hours (terminal half-life). Achieves steady state within 5-7 days.
Hepatic: ethinyl estradiol primarily via CYP3A4; norethindrone via reduction, sulfate and glucuronide conjugation. First-pass metabolism extensive. Enterohepatic recirculation.
Ethinyl estradiol is primarily metabolized by CYP3A4, with additional contributions from CYP2C9 and CYP2C19. Norethindrone acetate is metabolized via reduction and conjugation (glucuronidation and sulfation). Both undergo first-pass metabolism in the liver and intestinal wall.
Ethinyl estradiol (EE) and norethindrone (NET) are excreted in urine (40-60% as metabolites) and feces (20-30% as metabolites). NET is also excreted in bile and undergoes enterohepatic recirculation.
Renal: 30-50% (metabolites as glucuronide and sulfate conjugates). Fecal: 20-40% (biliary elimination of metabolites). Unchanged drug: <5% renal.
EE: ~97% bound to albumin; NET: ~61% bound to albumin, ~36% bound to SHBG.
Ethinyl estradiol: 97-98% bound to albumin and SHBG. Norethindrone: 90% bound to albumin and SHBG.
EE: ~6.5 L/kg; NET: ~4 L/kg. Reflects extensive tissue distribution.
Ethinyl estradiol: 2.5-4.0 L/kg. Norethindrone: 2.5-4.0 L/kg. Large Vd indicates extensive tissue distribution.
EE: ~40-45% (oral); NET: ~64% (oral) due to first-pass metabolism.
Oral: Ethinyl estradiol 38-48% (first-pass metabolism). Norethindrone 50-65% (first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Use is contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
No specific GFR-based dose adjustment; contraindicated in patients with renal impairment if associated with hyperkalemia or other contraindications.
Contraindicated in acute hepatic disease, hepatic adenomas, or history of cholestatic jaundice with prior oral contraceptive use. For Child-Pugh A (mild impairment), no adjustment; for Child-Pugh B or C (moderate to severe), contraindicated.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For mild impairment (Child-Pugh A), use with caution; no specific dose adjustment established.
Safety and efficacy not established in pediatric patients; use only after menarche and as per adult dosing if post-menarche.
Post-menarche adolescents: same dosing as adults (1 tablet daily for 21 days, then 7 placebo days). Weight-based dosing not applicable.
Not indicated for use in postmenopausal women. No dose adjustment necessary if used in women over 40 years who are premenopausal and not at increased risk of cardiovascular disease; however, consider lower dose formulations for women over 35 who smoke or have other risk factors.
Not indicated for postmenopausal women; use only in reproductive-age individuals.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age (especially >35 years) and with smoking intensity. Women over 35 who smoke should not use this product.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age (especially in women over 35 years) and with the number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders (DVT, PE, stroke, MI), especially in smokers >35 years. Hepatic neoplasia, gallbladder disease, hypertension, carbohydrate and lipid effects. Use caution with prediabetes/diabetes, migraine, SLE, hereditary angioedema. Discontinue if jaundice, visual disturbances, or suspected pregnancy. Do not use before menarche.
["Increased risk of thromboembolic events (e.g., stroke, MI, DVT, PE)","Hepatic neoplasia (benign and malignant)","Gallbladder disease","Hypertension","Carbohydrate and lipid effects","Ocular changes (e.g., retinal thrombosis)","Headache/migraine","Bleeding irregularities","Depression","Carcinoma risks (breast, cervical)","Hereditary angioedema","Chloasma","Reduced efficacy with concomitant CYP3A4 inducers","Pregnancy (should be ruled out before use)"]
Thrombophlebitis or thromboembolic disorders (current or history), cerebrovascular or coronary artery disease, known or suspected breast cancer or other estrogen-sensitive neoplasia, undiagnosed abnormal genital bleeding, pregnancy, known or suspected pregnancy, liver tumors (benign or malignant) or active liver disease, age >35 years and smoking, hypersensitivity to any component.
["Thrombophlebitis or thromboembolic disorders (current or history)","Cerebrovascular or coronary artery disease","Known or suspected breast carcinoma","Known or suspected estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior OC use","Hepatic adenoma or carcinoma","Known or suspected pregnancy","Hypersensitivity to any component of the product","Smoking in women over 35 years of age"]
Data Pending Review
Data Pending Review
No specific food interactions require restriction. Grapefruit juice may slightly increase ethinyl estradiol levels, but not clinically significant. Avoid St. John's Wort as it may reduce contraceptive efficacy.
No known significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically relevant. Avoid St. John's wort (herbal supplement) as it induces CYP3A4 and reduces contraceptive efficacy.
FDA Pregnancy Category X. Postmarketing studies have not identified an increased risk of major birth defects or miscarriages with combined hormonal contraceptives (CHCs) prior to pregnancy or inadvertently during early pregnancy. However, CHCs are contraindicated during pregnancy because they provide no benefit and may cause fetal harm. First trimester: No increased risk of congenital anomalies from inadvertent use. Second and third trimesters: Administration during pregnancy has been associated with an increased risk of adverse outcomes including hepatotoxicity (jaundice, cholestasis), estrogen-induced fetal masculinization of female genitalia, and potential long-term effects from androgen exposure. Use is contraindicated once pregnancy is confirmed.
FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester: Use associated with congenital anomalies, including cardiovascular defects and neural tube defects. Second and third trimesters: May cause fetal harm, including feminization of male fetuses and other adverse outcomes. Discontinue immediately if pregnancy occurs.
Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk. Estrogen-containing CHCs may reduce milk production and composition, particularly in the early postpartum period. The milk-to-plasma (M/P) ratio is approximately 0.6 for norethindrone and 0.01 for ethinyl estradiol. Use is not recommended during breastfeeding; progestin-only contraceptives are preferred alternatives.
Small amounts of ethinyl estradiol and norethindrone are excreted in human milk. No significant adverse effects reported in nursing infants. M/P ratio not established. May reduce milk production. Use with caution in breastfeeding women, especially during early postpartum period.
No dosing adjustments apply as Junel 1.5/30 is contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (increased hepatic metabolism, volume of distribution, renal clearance) would theoretically require dose adjustments, but the product is not indicated for use during pregnancy.
Not applicable; drug is contraindicated in pregnancy. No dose adjustments recommended as it should not be used.
Category C
Category C
Junel 1.5/30 is a monophasic oral contraceptive containing 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. It is indicated for contraception. The pill-free interval during the placebo week may trigger withdrawal bleeding. Consistent timing is crucial; a delay of more than 3 hours in taking the active pill requires backup contraception for 7 days. Consider potential drug interactions with hepatic enzyme inducers (e.g., rifampin, carbamazepine) that may reduce efficacy. Monitor blood pressure and liver function periodically.
Junel 1/20 is a low-dose combined oral contraceptive (COC) containing ethinyl estradiol 20 mcg and norethindrone acetate 1 mg. It is indicated for contraception but not for emergency contraception. Monitor for breakthrough bleeding, especially in first 3 months. CYP3A4 inducers (e.g., rifampin, St. John's wort) may reduce efficacy. Risk of venous thromboembolism (VTE) is lower than with 30-35 mcg EE pills but still present; counsel about smoking cessation if >35 years old.
Take one pill daily at the same time, starting on the first day of your menstrual period.If you miss a pill, follow the package insert instructions: if missed for less than 12 hours, take it immediately and continue; if missed for more than 12 hours, take the last missed pill and use backup contraception for 7 days.Common side effects include nausea, breast tenderness, and spotting, especially in the first few months.Smoking increases the risk of serious cardiovascular side effects, especially in women over 35 years old.If you experience severe headache, chest pain, leg pain, or vision changes, seek medical attention immediately.
Take one tablet daily at the same time; if a pill is missed, follow package instructions.Use backup contraception (e.g., condoms) for the first 7 days of starting or after a missed pill.Do not smoke while on this medication, especially if over 35, as it increases the risk of blood clots.Report signs of blood clots (leg pain/swelling, sudden chest pain, difficulty breathing) or liver problems (yellow skin/eyes, dark urine).Antibiotics (except rifampin) do not reduce contraceptive efficacy; verify with pharmacist.Mild side effects (nausea, headache, breast tenderness) often improve after 2-3 cycles.